Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | YAP1 | P46937 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761235 | 1.00 | PDCD1 (0.39) | PDCD1CD274GPR119PTPN1SLC6A2 | |
| SCHEMBL12593763 | 1.00 | PDCD1 (0.39) | PDCD1CD274GPR119PTPN1SLC6A2 | |
| SCHEMBL12648217 | 0.87 | GPR119 (0.38) | PDCD1CD274GPR119JAK1SSTR4 | |
| SCHEMBL16489772 | 0.86 | GPR119 (0.40) | PDCD1CD274GPR119SLC6A2SLC6A4 | |
| SCHEMBL18043583 | 0.76 | SLC6A2 (0.41) | GPR119SLC6A2SLC6A4SLC6A3JAK1 | |
| SCHEMBL31487849 | 0.75 | GPR119 (0.41) | GPR119YAP1JAK1 | |
| SCHEMBL3034148 | 0.74 | SLC6A2 (0.46) | GPR119SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12593766 | 0.74 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3RET | |
| SCHEMBL1761142 | 0.74 | SLC6A4 (0.38) | SLC6A2SLC6A4SLC6A3RET | |
| SCHEMBL30731964 | 0.73 | HTR3A (0.34) | PDCD1CD274GPR119SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199993-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8802698-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2183249-B1 | 8-Azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8481563-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110118306-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7902220-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | Theravance, Inc, (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118306-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | PDCD1 4116/4885CD274 2090/4885GPR119 341/4885 |
| US-20150051243-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | PDCD1 4116/4885CD274 2090/4885GPR119 341/4885 |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | PDCD1 4116/4885CD274 2090/4885GPR119 341/4885 |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | PDCD1 4116/4885CD274 2090/4885GPR119 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.